Listed

Oramed Pharmaceuticals Inc.: Form 10-Q for the period ended Jun 30, 2022

Filed with the SEC on Aug 10, 2022 and accepted by EDGAR at Aug 10, 2022, 16:45 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-04-01 to 2022-06-30$674.0kus-gaap:Revenues
Revenue6 months2022-01-01 to 2022-06-30$1.3mus-gaap:Revenues
Research and development3 months2022-04-01 to 2022-06-30$9.2mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2022-01-01 to 2022-06-30$15.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-04-01 to 2022-06-30−$11.4mus-gaap:OperatingIncomeLoss
Operating income6 months2022-01-01 to 2022-06-30−$22.7mus-gaap:OperatingIncomeLoss
Net income3 months2022-04-01 to 2022-06-30−$11.1mus-gaap:NetIncomeLoss
Net income6 months2022-01-01 to 2022-06-30−$21.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-04-01 to 2022-06-30$0.27us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2022-01-01 to 2022-06-30$0.54us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-04-01 to 2022-06-30$0.27us-gaap:EarningsPerShareBasic
Basic EPS6 months2022-01-01 to 2022-06-30$0.54us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-04-01 to 2022-06-3038,795,318 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2022-01-01 to 2022-06-3038,732,636 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2022-01-01 to 2022-06-30−$17.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2022-01-01 to 2022-06-30$67.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Current assetsAt period end2022-06-30$134.9mus-gaap:AssetsCurrent
Total assetsAt period end2022-06-30$162.3mus-gaap:Assets
Current liabilitiesAt period end2022-06-30$6.4mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2022-06-30$7.3mus-gaap:LongTermDebt
Shareholders' equityAt period end2022-06-30$153.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-22-046399. Last ingested by Listed: Nov 15, 2026, 04:14 ET. Listed shows no prices and gives no investment advice.